menu
    • menu
    [{"orgOrder":0,"company":"Sunshine Guojian Pharmaceutical","sponsor":"Numab Therapeutics","pharmaFlowCategory":"D","amount":"$15.2 million","upfrontCash":"Undisclosed","newsHeadline":"Numab and 3SBio\u2019s Sunshine Guojian Expand Partnership to Develop Novel T Cell Engager NM28","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Partnership","leadProduct":"ND021","moa":"4-1BB receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sunshine Guojian Pharmaceutical","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Sunshine Guojian Pharmaceutical \/ Numab Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Sunshine Guojian Pharmaceutical \/ Numab Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Sunshine Guojian Pharmaceutical

    Menu

    Sunshine Guojian Pharmaceutical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sunshine Guojian Pharmaceutical

                            China arrow
                            Luxepack
                            Not Confirmed

                            Sunshine Guojian Pharmaceutical

                            China arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ND021

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Numab Therapeutics

                            Deal Size : $15.2 million

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Numab and 3SBio’s Sunshine Guojian Expand Partnership to Develop Novel T Cell Engager NM28

                            Details : Under the agreement, Sunshine Guojian has the right to select up to five antibody molecules including ND021, emerging from the three multispecific antibody programs based on Numab’s R&D platform and has the licenses to develop and commercialize each of...

                            Brand Name : ND021

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            December 14, 2021

                            Lead Product(s) : ND021

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Numab Therapeutics

                            Deal Size : $15.2 million

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth